PGx to Play Role in Pfizer Drug Repositioning Partnership with Wash U
May 19, 2010
PGx to Play Role in Pfizer Drug Repositioning Partnership with Wash U
Under the five-year, $22.5 million partnership, Wash U researchers will investigate molecular-level mechanisms of compounds in Pfizer's pipeline and will seek to identify genetic variations linked to patient response.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Alzheimer's Prevention Study in Genetically Defined High-Risk Patients Includes Roche, Lilly Drugs
October 10, 2012 / Pharmacogenomics Reporter - Australian Team Developing Plasma Protein Panel for Predicting Amyloid Burden in Alzheimer's Patients
May 3, 2013 / ProteoMonitor - PGx Drugs Xalkori, Zelboraf Show Strong Growth in First Quarter of 2013
May 1, 2013 / Pharmacogenomics Reporter - At AACR, Early Providers of NGS-based Cancer Panels Debate 'Actionable' Mutations, Regulatory Issues
April 10, 2013 / Clinical Sequencing News - GWAS Unearths Variants with Ties to Alzheimer's Biomarker
April 4, 2013 / GenomeWeb Daily News